Celgene gets FDA OK for Inrebic

Press enter to search
Close search
Open Menu

Celgene gets FDA OK for Inrebic

By Sandra Levy - 08/19/2019
Celgene has received the Food and Drug Administration’s blessing for Inrebic (fedratinib) for the treatment of adult patients with intermediate-2 or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis.

“The approval of Inrebic is another important milestone for Celgene and underscores our commitment to people living with blood cancers,” Jay Backstrom, Celgene chief medical officer said. “We are excited to provide Inrebic as a new treatment option that may be used in patients with myelofibrosis, including patients previously treated with ruxolitinib.”

“Myelofibrosis can cause patients to suffer in many ways, including experiencing debilitating symptoms,” said Ruben Mesa, director of the Mays Cancer Center at UT Health San Antonio Cancer Center MD Anderson. “There has not been a new treatment approved for this disease in nearly a decade. With Inrebic, physicians and patients now have another option available for myelofibrosis.”